Trial Details
TERMINATEDBasic Information
| Clinical ID | c2108 |
|---|---|
| Identifier | NCT03961815 |
| Trial Title | Open-label Extension Study of Brazikumab in Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease|IBD |
| Interventions | DRUG: Brazikumab Induction Dose|DRUG: Brazikumab Maintenance Dose |
Participant Information
| Sponsor | AstraZeneca |
|---|---|
| City | Lincoln |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2020-01-06 |
|---|---|
| Primary Completion Date | 2023-09-19 |
| Completion Date | 2023-09-19 |